You are here

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

Last updated on August 13, 2019

Study Location
Eligibility criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Participants must be ≥ 18 years old.

- Participants with SCCHN or mCRCP.

- Participants must have histological diagnosis of solid tumors and provide tumor

- Measurable disease by RECIST v1.1 with at least 1 measurable lesion.

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.

- Adequate bone marrow, renal and liver function

- Highly effective contraceptive use by men with the ability to father a child or women
of childbearing potential.

- A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as
required by local regulations) at C1D1.

- Signed and dated informed consent.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known prior severe hypersensitivity to investigational products or any component in
their formulations, including known severe hypersensitivity reactions to monocolonal

- Known history of: immune-mediated colitis, inflammatory bowel disease, pneumonitis, or
pulmonary fibrosis.

- Active or prior autoimmune disease that might deteriorate when receiving an
immunostimulatory agent.

- Prior organ transplantation including allogenic stem cell transplantation.

- Vaccination within 4 weeks prior to C1D1 and while on trial is prohibited except for
administration of inactivated vaccines.

- Known symptomatic brain lesions requiring steroids.

- Known history of testing positive for human immunodeficiency virus (HIV or known
acquired immunodeficiency syndrome (AIDS).

- Positive HBV surface antigen or HCV test indicating acute or chronic infection..

- Active infection requiring systemic therapy

- Clinically significant (i.e., active) cardiovascular disease including the following:
documented left ventricular ejection fraction (LVEF) vascular accident/stroke; myocardial infarction; unstable angina; congestive heart
failure or serious cardiac arrhythmia (uncontrolled, clinically significant) requiring

- Diagnosis of any other malignancy within 2 years prior to C1D1, except for adequately
treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast,
bladder or of the cervix and for Combination A only, low-grade (Gleason 6 or below)
prostate cancer on surveillance with no plans for treatment intervention (e.g.,
surgery, radiation, or castration) or adequately treated prostate cancer.

- Current use of immunosuppressive medication at the time of study enrollment.

- Major surgery within 4 weeks prior to study enrollment.

- Conditions that may impair intake or absorption such as inability to swallow capsules
or tablets; known malabsorption syndrome; or baseline diarrhea ? Grade 1.

- Participation in other studies involving investigational drug(s) within 2 weeks prior
to C1D1.

Not yet recruiting
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.


Contact a representative by phone, email, or visiting the study website. Please see the references below:


Pfizer Clinical Trials Contact Center




[email protected]

Call Now